标签归档：ddd

GSK3186899(Synonyms: DDD-853651)

发表于由
回复

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

GSK3186899 (Synonyms: DDD-853651)

GSK3186899 (DDD-853651) 是 CRK12 的一个抑制剂，其对 L. donovani 的 EC50 值为 1.4 μM。

GSK3186899(Synonyms: DDD-853651)

GSK3186899 Chemical Structure

CAS No. : 1972617-87-0

规格 是否有货
100 mg   询价  
250 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

生物活性

GSK3186899 (DDD-853651) is an inhibitor of cdc-2-related kinase 12 (CRK12), with an EC50 of 1.4 μM for L. donovani in an intra-macrophage assay.

IC50 & Target

CRK12[1].
体外研究
(In Vitro)

GSK3186899 (Compound 7) is active against L. donovani in an intra-macrophage assay with an EC50 value of 1.4 μM, and shows good selectivity against mammalian THP-1 host cells (EC50 value>50 μM). This is not as potent as reported data for amphotericin B (EC50 value of 0.07 μM in the intra-macrophage assay), but is comparable to the clinically used drugs miltefosine and paromomycin (EC50 values of 0.9 μM and 6.6 μM, respectively). GSK3186899 is also active in cidal axenic amastigote assay (EC50 value of 0.1 μM). At a concentration of 0.2 μM, GSK3186899 is cytocidal at 96 h; increasing the concentration to 1.8 μM reduced this time to 48 h. GSK3186899 demonstrates a less than 10-fold variation in potency against a panel of Leishmania-derived lines. GSK3186899 is also more active in a panel of Leishmania lines using human peripheral blood mononuclear cells as the host cells[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究
(In Vivo)

In the mouse model of infection, GSK3186899 demonstrates comparable activity to the front-line drug miltefosine, reducing parasite levels by 99% when dosed orally twice a day for 10 days at 25 mg/kg. The efficacy of treatment is dependent on dose, frequency, and duration (10 days better than 5). The non-clinical safety data for GSK3186899 suggests a suitable therapeutic window for progression into regulatory preclinical studies. Non-GLP preclinical assessment of cardiovascular effects and genotoxicity does not reveal any issues that would prevent further development. In addition, there are no notable adverse effects in a rat seven-day repeat-dose oral toxicity study with respect to clinical chemistry and histopathology at all doses tested. Both the in vivo efficacy and safety profile of GSK3186899 support progression to definitive safety studies[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial

分子量

491.53

Formula

C19H28F3N7O3S
CAS 号

1972617-87-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
参考文献

  • [1]. Wyllie S, et al. Cyclin-dependent kinase 12 is a drug target for visceral leishmaniasis. Nature. 2018 Aug;560(7717):192-197.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Mitotane(Synonyms: 米托坦; 2,4′-DDD; o,p’-DDD)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Mitotane (Synonyms: 米托坦; 2,4′-DDD; o,p’-DDD) 纯度: 99.92%

Mitotane(2,4′-DDD)是DDD的同分异构体和DDT的衍生物，有抗癌活性，可作用于肾上腺皮质癌。

Mitotane(Synonyms: 米托坦; 2,4′-DDD; o,p

Mitotane Chemical Structure

CAS No. : 53-19-0

规格 价格 是否有货 数量
Free Sample (0.1-0.5 mg)   Apply now  
10 mM * 1 mL in DMSO ￥563 In-stock
100 mg ￥512 In-stock
500 mg ￥837 In-stock
1 g   询价  
5 g   询价  

* Please select Quantity before adding items.

Mitotane 相关产品

•相关化合物库:

  • Drug Repurposing Compound Library Plus
  • FDA-Approved Drug Library Plus
  • FDA-Approved Drug Library Mini
  • Bioactive Compound Library Plus
  • Apoptosis Compound Library
  • FDA-Approved Drug Library
  • Anti-Cancer Compound Library
  • Drug Repurposing Compound Library
  • Orally Active Compound Library
  • FDA Approved & Pharmacopeial Drug Library
  • Drug-Induced Liver Injury (DILI) Compound Library
  • Rare Diseases Drug Library

生物活性

Mitotane(2,4′-DDD), an isomer of DDD and derivative of DDT, is an antineoplastic medication used in the treatment of adrenocortical carcinoma. IC50 value: Target: Mitotane alters steroid peripheral metabolism, directly suppresses the adrenal cortex and alters cortisone metabolism leading to hypocortisolism. Side effects as reported by Schteinberg et al. include anorexia and nausea (88%), diarrhea (38%), vomiting (23%), decreased memory and ability to concentrate (50%), rash (23%), gynecomastia (50%), arthralgia (19%), and leukopenia (7%).

Clinical Trial

分子量

320.04

Formula

C14H10Cl4
CAS 号

53-19-0
中文名称

米托坦；密妥坦；氯苯二氯乙烷；曼托坦；解腺瘤
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : ≥ 100 mg/mL (312.46 mM)

* “≥” means soluble, but saturation unknown.

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.1246 mL 15.6230 mL 31.2461 mL
5 mM 0.6249 mL 3.1246 mL 6.2492 mL
10 mM 0.3125 mL 1.5623 mL 3.1246 mL

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

  • 1.

    请依序添加每种溶剂： 10% DMSO    40% PEG300    5% Tween-80    45% saline

    Solubility: ≥ 2.5 mg/mL (7.81 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.81 mM，饱和度未知) 的澄清溶液。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。

    将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液

  • 2.

    请依序添加每种溶剂： 10% DMSO    90% (20% SBE-β-CD in saline)

    Solubility: 2.5 mg/mL (7.81 mM); Suspended solution; Need ultrasonic

    此方案可获得 2.5 mg/mL (7.81 mM) 的均匀悬浊液，悬浊液可用于口服和腹腔注射。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。

    将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
  • 3.

    请依序添加每种溶剂： 10% DMSO    90% corn oil

    Solubility: ≥ 2.5 mg/mL (7.81 mM); Clear solution

    此方案可获得 ≥ 2.5 mg/mL (7.81 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。

    以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

*以上所有助溶剂都可在 上海金畔生物科技有限公司 网站选购。
参考文献

  • [1]. Gentilin E, Tagliati F, Terzolo M, Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. J Endocrinol. 2013 Jul 29;218(3):275-285.

    [2]. Lehmann TP, Wrzesiński T, Jagodziński PP. The effect of mitotane on viability, steroidogenesis and gene expression in NCI H295R adrenocortical cells. Mol Med Rep. 2013 Mar;7(3):893-900.

    [3]. Takeshita A, Igarashi-Migitaka J, Koibuchi N, Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. J Endocrinol. 2013 Feb 15;216(3):297-305.

    [4]. Ederhy S, Cohen A, Dufaitre G, No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma. J Endocrinol Invest. 2012 Nov;35(10):911-4.

    [5]. Alexandraki KI, Kaltsas GA, le Roux CW, Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clin Endocrinol (Oxf). 2010 Mar;72(3):305-11.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

Madrasin(Synonyms: DDD00107587)

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

Madrasin (Synonyms: DDD00107587) 纯度: 99.90%

Madrasin (DDD00107587) 是一种剪接抑制剂，可在体外阻止剪接中间体和产物的形成，并干扰剪接体组装途径中的一个或多个早期步骤。Madrasin 还能在体外抑制 pre-mRNA 的剪接，并修饰细胞中内源性 pre-mRNA 的剪接。

Madrasin(Synonyms: DDD00107587)

Madrasin Chemical Structure

CAS No. : 374913-63-0

规格 价格 是否有货 数量
5 mg ￥660 In-stock
10 mg ￥990 In-stock
25 mg ￥1980 In-stock
50 mg ￥3300 In-stock
100 mg ￥5500 In-stock
200 mg   询价  
500 mg   询价  

* Please select Quantity before adding items.

Madrasin 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Anti-Cancer Compound Library

生物活性

Madrasin (DDD00107587) is a splicing inhibitor that prevents formation of both splicing intermediates and products in vitro and interferes with one or more early steps in the pathway of spliceosome assembly. Madrasin also can inhibit pre-mRNA splicing in vitro and modify splicing of endogenous pre-mRNA in cells[1].

IC50 & Target

pre-mRNA splicing[1]
体外研究
(In Vitro)

Madrasin (10-30 μM; 4-24 hours; HeLa cells) treatment inhibits the splicing of each of the RIOK3, BRD2, and Hsp40, MCL1, CCNA2, AURKA and p27 pre-mRNAs in both HeLa and HEK293 cells[1].
Madrasin (10-30 μM; 4-24 hours; HeLa and HEK293 cells) treatment shows a dose- and time-dependent inhibitory effect on cell cycle progression[1].

上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR[1]

Cell Line: HeLa cells
Concentration: 10 μM, 20 μM, or 30 μM
Incubation Time: 4 hours, 8 hours, or 24 hours
Result: Increased in inhibition of pre-mRNA splicing.

Cell Cycle Analysis[1]

Cell Line: HeLa and HEK293 cells
Concentration: 10 μM, 20 μM, or 30 μM
Incubation Time: 4 hours, 8 hours, or 24 hours
Result: In the presence of 10 μM 8 hours after treatment, the proportion of cells in G2, M, and S phases increased, with a concomitant decrease in the number of G1 phase cells. This effect increased over time, with >40% of cells in G2 and M phase and >50% in S phase 24 hours.

分子量

311.34

Formula

C16H17N5O2
CAS 号

374913-63-0
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
溶解性数据
In Vitro: 

DMSO : 2 mg/mL (6.42 mM; Need ultrasonic)

H2O : < 0.1 mg/mL (insoluble)

配制储备液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 3.2119 mL 16.0596 mL 32.1192 mL
5 mM 0.6424 mL 3.2119 mL 6.4238 mL
10 mM — — —

*

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。
参考文献

  • [1]. Andrea Pawellek et al. Identification of Small Molecule Inhibitors of Pre-mRNA Splicing. J Biol Chem, 2014 Dec 12, 289(50): 34683-34698.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

上海雷磁工业电导率仪DDD-32D

发表于由

上海雷磁工业电导率仪DDD-32D

  • 品牌 雷磁|lei-ci
  • 型号 DDD-32D
  • 商品详情

    测量范围： 电导率(0.000~10000)μS/cm

    基本误差： ±3.0%(FS)±1个字

    电子单元稳定性： ±1%(FS)/24h

    被测溶液条件： 被测溶液温度:(0~60)°C

    被测介质压力:0.5×106Pa

    尺寸及重量： 电子单元外形尺寸,mm:160×160×200

    电子单元开孔尺寸,mm:145×145

    进、出口连接:内孔Φ8.5不锈钢管子

    电子单元重量:约2kg

    使用环境： a)环境温度:(0~40)°C

    b)相对湿度:不大于90%

    c)供电电源:交流电压(220±22)V

    频率（50±0.5）Hz

    d)周围空气中无腐蚀性气体存在；

    e)周围除地磁场外无其它影响性能的电磁场和振动存在

     

    DDD-32D 主要特点:

    2 1/2位LCD液晶显示

    具有（0~10）mA、（4~20）mA隔离输出信号可选择

    电导池常数有0.01、0.1、1.0cm-1三种类型

    配套发送器：DDDF-23D型电导发送器

    电导池材料：PVC塑料

     

    电导率测量范围μS/cm

    电导池常数cm-1

    0～0.1、0～1、0～10、0～100

    0.01(主量程)

    0～1、0～10、0～100、0～1000

    0.1

    0～10、0～100、0～1000、0～10000

    1.0

     

    • Mitotane-d4(Synonyms: 2,4′-DDD-d4; o,p’-DDD-d4)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Mitotane-d4 (Synonyms: 2,4′-DDD-d4; o,p’-DDD-d4)

    Mitotane-d4 (2,4′-DDD-d4) 是 Mitotane 的氘代物。Mitotane(2,4′-DDD)是DDD的同分异构体和DDT的衍生物，有抗癌活性，可作用于肾上腺皮质癌。

    Mitotane-d4(Synonyms: 2,4′-DDD-d4; o,p

    Mitotane-d4 Chemical Structure

    CAS No. : 2714431-79-3

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    Mitotane-d4 (2,4′-DDD-d4) is the deuterium labeled Mitotane. Mitotane (2,4′-DDD), an isomer of DDD and derivative of DDT, is an antineoplastic medication used in the treatment of adrenocortical carcinoma.

    体外研究
    (In Vitro)

    Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    324.07

    Formula

    C14H6D4Cl4
    CAS 号

    2714431-79-3
    中文名称

    米托坦 d4
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

      [2]. Gentilin E, Tagliati F, Terzolo M, Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. J Endocrinol. 2013 Jul 29;218(3):275-285.

      [3]. Lehmann TP, Wrzesiński T, Jagodziński PP. The effect of mitotane on viability, steroidogenesis and gene expression in NCI H295R adrenocortical cells. Mol Med Rep. 2013 Mar;7(3):893-900.

      [4]. Takeshita A, Igarashi-Migitaka J, Koibuchi N, Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. J Endocrinol. 2013 Feb 15;216(3):297-305.

      [5]. Ederhy S, Cohen A, Dufaitre G, No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma. J Endocrinol Invest. 2012 Nov;35(10):911-4.

      [6]. Alexandraki KI, Kaltsas GA, le Roux CW, Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clin Endocrinol (Oxf). 2010 Mar;72(3):305-11.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    Mitotane-d4(Synonyms: 2,4′-DDD-d4; o,p’-DDD-d4)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Mitotane-d4 (Synonyms: 2,4′-DDD-d4; o,p’-DDD-d4)

    Mitotane-d4 (2,4′-DDD-d4) 是 Mitotane 的氘代物。Mitotane(2,4′-DDD)是DDD的同分异构体和DDT的衍生物，有抗癌活性，可作用于肾上腺皮质癌。

    Mitotane-d4(Synonyms: 2,4′-DDD-d4; o,p

    Mitotane-d4 Chemical Structure

    CAS No. : 2714431-79-3

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    Mitotane-d4 (2,4′-DDD-d4) is the deuterium labeled Mitotane. Mitotane (2,4′-DDD), an isomer of DDD and derivative of DDT, is an antineoplastic medication used in the treatment of adrenocortical carcinoma.

    体外研究
    (In Vitro)

    Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

    Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    324.07

    Formula

    C14H6D4Cl4
    CAS 号

    2714431-79-3
    中文名称

    米托坦 d4
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

      [2]. Gentilin E, Tagliati F, Terzolo M, Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. J Endocrinol. 2013 Jul 29;218(3):275-285.

      [3]. Lehmann TP, Wrzesiński T, Jagodziński PP. The effect of mitotane on viability, steroidogenesis and gene expression in NCI H295R adrenocortical cells. Mol Med Rep. 2013 Mar;7(3):893-900.

      [4]. Takeshita A, Igarashi-Migitaka J, Koibuchi N, Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. J Endocrinol. 2013 Feb 15;216(3):297-305.

      [5]. Ederhy S, Cohen A, Dufaitre G, No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma. J Endocrinol Invest. 2012 Nov;35(10):911-4.

      [6]. Alexandraki KI, Kaltsas GA, le Roux CW, Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clin Endocrinol (Oxf). 2010 Mar;72(3):305-11.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

    Mitotane-d4(Synonyms: 2,4′-DDD-d4; o,p’-DDD-d4)

    发表于由

    上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

    Mitotane-d4 (Synonyms: 2,4′-DDD-d4; o,p’-DDD-d4)

    Mitotane-d4 (2,4′-DDD-d4) 是 Mitotane 的氘代物。Mitotane(2,4′-DDD)是DDD的同分异构体和DDT的衍生物，有抗癌活性，可作用于肾上腺皮质癌。

    Mitotane-d4(Synonyms: 2,4′-DDD-d4; o,p

    Mitotane-d4 Chemical Structure

    CAS No. : 2714431-79-3

    规格 是否有货
    100 mg   询价  
    250 mg   询价  
    500 mg   询价  

    * Please select Quantity before adding items.

    生物活性

    Mitotane-d4 (2,4′-DDD-d4) is the deuterium labeled Mitotane. Mitotane (2,4′-DDD), an isomer of DDD and derivative of DDT, is an antineoplastic medication used in the treatment of adrenocortical carcinoma.

    体外研究
    (In Vitro)

    Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs[1].

    上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
    分子量

    324.07

    Formula

    C14H6D4Cl4
    CAS 号

    2714431-79-3
    中文名称

    米托坦 d4
    运输条件

    Room temperature in continental US; may vary elsewhere.
    储存方式

    Please store the product under the recommended conditions in the Certificate of Analysis.
    参考文献

    • [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.

      [2]. Gentilin E, Tagliati F, Terzolo M, Mitotane reduces human and mouse ACTH-secreting pituitary cell viability and function. J Endocrinol. 2013 Jul 29;218(3):275-285.

      [3]. Lehmann TP, Wrzesiński T, Jagodziński PP. The effect of mitotane on viability, steroidogenesis and gene expression in NCI H295R adrenocortical cells. Mol Med Rep. 2013 Mar;7(3):893-900.

      [4]. Takeshita A, Igarashi-Migitaka J, Koibuchi N, Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor. J Endocrinol. 2013 Feb 15;216(3):297-305.

      [5]. Ederhy S, Cohen A, Dufaitre G, No evidence for relevant QT interval prolongation in mitotane-treated patients with adrenocortical carcinoma. J Endocrinol Invest. 2012 Nov;35(10):911-4.

      [6]. Alexandraki KI, Kaltsas GA, le Roux CW, Assessment of serum-free cortisol levels in patients with adrenocortical carcinoma treated with mitotane: a pilot study. Clin Endocrinol (Oxf). 2010 Mar;72(3):305-11.

    所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务